Evidence map›Paper›PMID 32511851›Full record

ArticleJournal of prosthodontics : official journal of the American College of Prosthodontists2020

Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse.

Avinash S Bidra, Jesse S Pelletier, Jonna B Westover, Samantha Frank, Seth M Brown, Belachew Tessema

2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Journal of prosthodontics : official journal of the American College of Prosthodontists, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 87 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 7 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04517188 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19

TypeinterventionalSponsorHalodine LLCRan2021 to 2021Enrolled40ConditionsSARS-CoV-2 InfectionArmsPovidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
NCT04559035 nacompletednot on this map

Nasal Irrigation to Reduce COVID-19 Morbidity

TypeinterventionalSponsorAugusta UniversityRan2020 to 2021Enrolled239ConditionsCovid19ArmsNasal lavage
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 7 syntheses or guidelines pooled it, 161 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Disinfection methods against SARS-CoV-2: a systematic review.The Journal of hospital infection · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Virucidal activity and mechanism of action of cetylpyridinium chloride against SARS-CoV-2.Journal of oral and maxillofacial surgery, medicine, and pathology · 2022
    Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Avinash S BidraDepartment of Reconstructive Sciences, University of Connecticut Health Center, Farmington, CT.ORCID https://orcid.org/0000-0001-8831-8096
Jesse S PelletierOcean Ophthalmology Group, Miami, FL.
Jonna B WestoverThe Institute for Antiviral Research at Utah State University, Logan, UT.
Samantha FrankDepartment of Otolaryngology, University of Connecticut Health Center, Farmington, CT.
Seth M BrownDepartment of Otolaryngology, University of Connecticut Health Center, Farmington, CT.
Belachew TessemaDepartment of Otolaryngology, University of Connecticut Health Center, Farmington, CT.
ProHealth Care · USUConn Health · USOphthalmology Associates (United States) · USUtah State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone-iodine (PVP-I) against SARS-CoV-2 ('corona virus') to mitigate the risk and transmission of the virus in the dental practice. MATERIALS AND

methodsThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) USA-WA1/2020 strain, virus stock was tested against oral antiseptic solutions consisting of aqueous povidone-iodine (PVP-I) as the sole active ingredient. The PVP-I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media without any virus was added to 2 tubes of the compounds to serve as toxicity and neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and water only as a negative control. The test solutions and virus were incubated at room temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was quantified by standard end-point dilution assay and the log reduction value (LRV) of each compound compared to the negative (water) control was calculated.

resultsPVP-I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%, completely inactivated SARS-CoV-2 within 15 seconds of contact. The 70% ethanol control group was unable to completely inactivate SARS-CoV-2 after 15 seconds of contact, but was able to inactivate the virus at 30 seconds of contact.

conclusionsPVP-I oral antiseptic preparations rapidly inactivated SARS-CoV-2 virus in vitro. The viricidal activity was present at the lowest concentration of 0.5 % PVP-I and at the lowest contact time of 15 seconds. This important finding can justify the use of preprocedural oral rinsing with PVP-I (for patients and health care providers) may be useful as an adjunct to personal protective equipment, for dental and surgical specialties during the COVID-19 pandemic.

Indexed as

Anti-Infective Agents, LocalCoronavirus InfectionsPandemicsPneumonia, ViralBetacoronavirusCOVID-19HumansPovidone-IodineSARS-CoV-2Anti-Infective Agents, LocalPovidone-Iodinecorona virusdental safetyoral rinsepovidone-iodineSARS-CoV-2

Identifiers

PMID32511851
PMCPMC7300649
OpenAlexW3033233914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.